Neoleukin Therapeutics Inc

NASDAQ:NLTX  
10.39
-0.24 (-2.26%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Neoleukin Therapeutics Inc Stock, NASDAQ:NLTX

188 East Blaine Street, Suite 450, Seattle, Washington 98102
United States of America
Phone: +1.866.245.0312
Number of Employees: 70

Description

Neoleukin Therapeutics, Inc. operates as a biopharmaceutical company, which computational methods to design de novo protein therapeutics. The firm address significant medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.